LIESTAL, Switzerland & PARIS-(BUSINESS WIRE)-Regulatory News: Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Paris:IPN - News) (Euronext: IPN; ADR: IPSEY) today announced a license agreement for the development and commercialization of fipamezole (antagonist of the (…)
[Read article]
[Source: BioSpace]
Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, (…)
[Read article]
[Source: Medical News Today]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). (…)
[Read article]
[Source: Business Wire]
01.09.2010 - Takeda Pharmaceutical Company Limited announced that it has received an official notice from the Pharmaceutical Development Support Center with regard to the granting of a government subsidy for which it had applied. Takeda was notified in writing on July 6 of this (…)
[Read article]
[Source: Bionity.com]
Highlighted Links Industrial Info Resources SUGAR LAND, TX-(Marketwire - August 26, 2010) - Researched by Industrial Info Resources (Sugar Land, Texas) - Takeda Pharmaceutical Company Limited (PINKSHEETS:TKPHF) (Osaka, Japan) has completed a major expansion project at the (…)
[Read article]
[Source: Marketwire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/360241/best_practices_in) has announced the addition of the "Best Practices in Working with Patient Advocacy Groups: Building Effective Relationships" report to their offering. Best (…)
[Read article]
[Source: Business Wire]
In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same about 4 percent for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b5aaab/pharmaceutical_new) has announced the addition of the "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 2010" report to their (…)
[Read article]
[Source: Business Wire]
Bloomberg - Takeda Pharmaceutical Co. s diabetes drug Actos causes as many heart problems as Avandia, the GlaxoSmithKline Plc pill that had a decline in sales after being linked to higher heart-disease rates, a study found.
[Read article]
[Source: BioSpace]
ScienceDaily (Aug. 24, 2010) A new analysis of data on patients covered by a single insurance company reports that risks of heart disease events and death were no different between patients who took the diabetes drugs rosiglitazone or pioglitazone. In this analysis, (…)
[Read article]
[Source: ScienceDaily]
Erythropoiesis stimulating agents (ESAs) are effective drugs that correct anemia in patients with chronic kidney disease (CKD). Recombinant human erythropoietin (EPO), the first ESA that became available more than 20 years ago, is similar to the naturally occurring molecule. In (…)
[Read article]
[Source: NCBI PubMed]
24.08.2010 - Takeda Pharmaceutical Company Limited announced that an additional indication for "NESINA (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a (…)
[Read article]
[Source: Bionity.com]
Takeda Pharmaceutical Company Limited ("Takeda") announced that an additional indication for "NESINA" (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1b2677/takeda_pharmaceuti) has announced the addition of the "Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile" company profile to their offering. This analysis examines the historical (…)
[Read article]
[Source: Business Wire]
Sepsis is characterized by an excessive host response to infection. Toll-like receptor (TLR)s are essential for triggering this type of host immune response. TLR4 mediates recognition of lipopolysaccharide from Gram-negative bacteria and is an important initiator of sepsis. In (…)
[Read article]
[Source: NCBI PubMed]
We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner. TAK-070 bound to full-length BACE1, but not to truncated (…)
[Read article]
[Source: NCBI PubMed]
Bloomberg - Takeda Pharmaceutical Co. said an unfulfilled need for medicines to treat lifestyle diseases including diabetes will spur sales growth as its biggest drug Actos faces generic competition.
[Read article]
[Source: BioSpace]
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA(R) (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is (…)
[Read article]
[Source: BioSpace]
13.08.2010 - Santhera Pharmaceuticals announced today that the European Patent Office granted patent protection for the use of idebenone (brand name Catena/Sovrima) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. A pivotal Phase III study (…)
[Read article]
[Source: Bionity.com]
VANCOUVER, BRITISH COLUMBIA-(Marketwire - Aug. 12, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM), a leader in RNA interference (RNAi) therapeutics, today announced its financial and operational results for the second quarter ended June 30, 2010. Dr. Mark J. Murray, (…)
[Read article]
[Source: Marketwire]
CHICAGO-(BUSINESS WIRE)-The iBIO Institute today announced the two winners of the fourth annual iBIO Institute iCON Awards, considered by many to be the region s most prestigious honor for life sciences educators and researchers. The iCON Awards celebrate the accomplishments (…)
[Read article]
[Source: Business Wire]
A reliable and practical cytochrome P450 (CYP) 3A induction assay with cryopreserved human hepatocytes in a 96-well format was developed. Various 96-well plates with different basement membrane were evaluated using prototypical inducers, rifampicin, phenytoin, and carbamazepin. (…)
[Read article]
[Source: NCBI PubMed]
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II (…)
[Read article]
[Source: BioSpace]
Cocrystal has attracted much attention in order to improve poor physicochemical properties, since cocrystal former crystallize with the ionic drugs as well as nonionic drugs. Cocrystal screening was usually conducted by crystallization, slurry and co-grinding techniques, (…)
[Read article]
[Source: NCBI PubMed]
BACKGROUND: Spinal and bulbar muscular atrophy is a hereditary motor neuron disease caused by the expansion of a polyglutamine tract in the androgen receptor. At present there are no treatments for spinal and bulbar muscular atrophy, although leuprorelin suppressed the (…)
[Read article]
[Source: NCBI PubMed]
Am J Psychiatry. |-| Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. |-| Dr. Burt has served as consultant or adviser to, or on the speakers bureau of, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Noven Pharmaceuticals, Takeda Pharmaceuticals, and Wyeth-Ayerst. Dr. (…)
[Read article]
[Source: NCBI PubMed]
Affymax, Inc. and Takeda Pharmaceutical Company Limited announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States. (…)
[Read article]
[Source: Medical News Today]
BETHESDA, Md.-(BUSINESS WIRE)-Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today reported its consolidated financial results for the quarter and six months ended June 30, 2010. In addition, we continue to work towards resolution of our ongoing dispute with Takeda (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010. We reported another solid quarter as we prepare for our next growth phase with near-term opportunities to add (…)
[Read article]
[Source: Business Wire]
PALO ALTO, Calif. & OSAKA-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide ¢/peginesatide, for the (…)
[Read article]
[Source: Business Wire]
PALO ALTO, Calif. & OSAKA-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide ¢/peginesatide, for the (…)
[Read article]
[Source: BioSpace]
PALO ALTO, Calif.-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The (…)
[Read article]
[Source: BioSpace]
PALO ALTO, Calif.-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The (…)
[Read article]
[Source: Business Wire]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights. We remain on track to finish 2010 with an (…)
[Read article]
[Source: Business Wire]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma (MCL). The data, derived from an analysis of (…)
[Read article]
[Source: Business Wire]
DEERFIELD, Ill.-(BUSINESS WIRE)-Actient Pharmaceuticals, LLC ( Actient ), a portfolio company of GTCR, announced today the company successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA ( UCB ), (…)
[Read article]
[Source: Business Wire]
CHICAGO-(BUSINESS WIRE)-GTCR, one of the country s leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an (…)
[Read article]
[Source: Business Wire]
LEXINGTON, Mass.-(BUSINESS WIRE)-AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer (…)
[Read article]
[Source: Business Wire]
WILMINGTON, N.C.-(BUSINESS WIRE)-PPD, Inc. (Nasdaq: PPDI) today reported its financial and operating results for the second quarter ended June 30, 2010. We were pleased to continue the momentum from the first quarter necessary to achieve our 2010 goals PPD recorded net (…)
[Read article]
[Source: Business Wire]
Proton pump inhibitors (PPIs) are widely used in the treatment of acid-related diseases. However, several unmet medical needs, such as suppression of nocturnal acid breakthrough and rapid symptom relief, remain. In this study, we investigated the pharmacological effects of (…)
[Read article]
[Source: NCBI PubMed]
Prostate cancer is the most common form of cancer in males in the United States, and the second leading cause of cancer death. Initially, most cases of prostate cancer respond well to hormone therapy; however, resistance often develops rapidly, leading to castration-resistant (…)
[Read article]
[Source: NCBI PubMed]
BERKELEY, Calif., July 26, 2010 (GLOBE NEWSWIRE) - XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO - (…)
[Read article]
[Source: BioSpace]